Corcept Therapeutics (NASDAQ:CORT) Upgraded by StockNews.com to Buy Rating
Corcept Therapeutics (NASDAQ:CORT – Get Free Report) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday. Several other equities analysts also recently issued reports on CORT. Canaccord Genuity Group upped their price objective on shares of Corcept Therapeutics from $130.00 to $142.00 and […]
Corcept Therapeutics (NASDAQ:CORT – Get Free Report) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday. Several other equities analysts also recently issued reports on CORT. Canaccord Genuity Group upped their price objective on shares of Corcept Therapeutics from $130.00 to $142.00 and […]
